This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Enzo Biochem Reports Fourth Quarter And Fiscal Year Results

Legal costs remained high throughout the year, and are expected to continue above historical levels, due to preparation for next month’s scheduled trial in New York Federal District Court and the successful prosecution of the case against Life Technologies, which nonetheless resulted in additional expenses due to post judgment filings. Finances remain satisfactory, and we regard the overall outlook for Enzo, given our depth and breadth, as well as the stringent staff and cost measures we have taken to strengthen results, as promising.”

Quarterly and Fiscal Year Results

For the quarter, total revenues were $23.3 million, compared with $22.6 million in the preceding quarter and $26.4 million a year ago. Fiscal 2013 revenues totaled $93.7 million, compared with $103.1 million. Net loss for the quarter amounted to $3.1 million, or ($0.08) per share, basic and fully diluted, compared to a net loss of $5.8 million, or ($0.15) per share, basic and fully diluted sequentially and a net loss of $27.1 million, or ($0.69) per share, basic and fully diluted, a year ago (including an impairment charge of $22.4 million). On July 31, 2013, total current assets amounted to $32.6 million, including $9.0 million of cash and cash equivalents. Working capital amounted to $8.7 million .

Sector Results

At Enzo Clinical Labs, despite organic growth, lower reimbursements and policy changes from certain payers, fourth quarter revenues amounted to $14.0 million, compared to $13.4 million in the preceding quarter and $15.9 million a year ago. Gross margin at $4.2 million remained essentially even quarter over quarter, with gross profit percentage equal to 30% in both periods, but declined approximately $2 million year over year, when the gross profit percentage was 40%. The operating loss improved by approximately $0.6 million sequentially, to $1.5 million, and compared to an operating loss a year ago of $0.8 million.

2 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs